INTENSITY THERAPEUTICS INC (INTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$4.02-1.71%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — EPS loss reduction to less negative levels: EPS -0.99 vs -0.73 target.
Intensity Therapeutics aims to revolutionize cancer treatment with new drug delivery. The company has a strong research pipeline targeting immuno-oncology therapies. Recent analyst EPS revisions show slight improvement from -0.84 to -0.73 next quarter. The firm is raising capital to support development and growth.
The company is loss-making with repeated earnings misses and no revenue forecast. Its stock has fallen 14.6% from highs and faces high risk. There is no clear near-term profitability or revenue growth visible. Debt issuance and Nasdaq delisting risks remain concerns.
No clear market consensus or fair value is available. Analysts expect continued losses with EPS around -0.73 next quarter and -3.13 for the current year. The market likely prices in ongoing losses and uncertainty about commercialization.
Breaks if: ATM capacity falls below $30 million or inability to raise funds
Breaks if: EPS remains below -0.73 next quarter
Failure to achieve key clinical or regulatory milestones within 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and its recent performance has been inconsistent, making the long-term thesis uncertain.
The market seems to have low expectations given the company's recent earnings misses and overall loss-making status. Investors may be cautious, reflecting a muted reaction to recent financial results.
Management is focused on resuming clinical trials and maintaining cash flow, but the trajectory is mixed. There is a high risk of missing earnings expectations in the near term, which could further impact investor sentiment.
The thesis hinges on the company's ability to resume enrollment in clinical studies and the performance of key sector peers. Additionally, broader economic conditions, such as job growth, could influence investor confidence.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company is making regulatory progress. It aims to complete enrollment for a study by the end of 2027. However, it recently missed earnings expectations. This miss raises concerns about its financial performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, INTS will need to navigate significant challenges while attempting to regain momentum in its clinical programs. Not investment advice.